Co., Ltd. ("Sanyou Bio") and Wenzhou KanryBio Biotech Co., Ltd. ("KanryBio") announced a strategic collaboration agreement. The partnership will focus on the joint development of key reagents and ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

Ready to expand the possibilities of biomarker science? The Simoa® Accelerator Laboratory is a full-service center for biopharmaceutical research. The Accelerator Lab provides exploratory protein ...

Please provide your email address to receive an email when new articles are posted on . ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for ...

Interest in biomarkers has exploded in recent years, driven by improvements in data collection and analysis, burgeoning interest in personalized medicine, and efforts to increase the success rate for ...

Develop custom Simoa® assays that drive breakthroughs from discovery to diagnostics. Simoa® technology offers flexibility, sensitivity, and simplicity. Utilize the proprietary reagents along with the ...

Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...

First central lab in EU to perform this blood-based assay under IVDR/LDT regulations, supporting inclusion and exclusion criteria in Alzheimer’s clinical trials Achieving IVDR validation for the ...